XTRA:EUZ

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Eckert & Ziegler Strahlen- und Medizintechnik

Executive Summary

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide.


Snowflake Analysis

Flawless balance sheet with proven track record and pays a dividend.

Share Price & News

How has Eckert & Ziegler Strahlen- und Medizintechnik's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EUZ has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.5%

EUZ

0.9%

DE Medical Equipment

2.1%

DE Market


1 Year Return

54.6%

EUZ

20.3%

DE Medical Equipment

2.1%

DE Market

Return vs Industry: EUZ exceeded the German Medical Equipment industry which returned 20.4% over the past year.

Return vs Market: EUZ exceeded the German Market which returned 3% over the past year.


Shareholder returns

EUZIndustryMarket
7 Day3.5%0.9%2.1%
30 Day7.5%-2.8%-0.8%
90 Day18.7%15.1%20.1%
1 Year56.5%54.6%21.8%20.3%4.2%2.1%
3 Year348.7%328.2%121.8%117.1%3.7%-4.7%
5 Year642.6%574.2%248.4%234.4%10.7%-4.0%

Price Volatility Vs. Market

How volatile is Eckert & Ziegler Strahlen- und Medizintechnik's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eckert & Ziegler Strahlen- und Medizintechnik undervalued compared to its fair value and its price relative to the market?

37.39x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: EUZ (€154.4) is trading above our estimate of fair value (€101.42)

Significantly Below Fair Value: EUZ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: EUZ is good value based on its PE Ratio (37.4x) compared to the Medical Equipment industry average (53x).

PE vs Market: EUZ is poor value based on its PE Ratio (37.4x) compared to the German market (21.1x).


Price to Earnings Growth Ratio

PEG Ratio: EUZ is poor value based on its PEG Ratio (2.9x)


Price to Book Ratio

PB vs Industry: EUZ is overvalued based on its PB Ratio (5.5x) compared to the DE Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Eckert & Ziegler Strahlen- und Medizintechnik forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

13.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EUZ's forecast earnings growth (13% per year) is above the savings rate (0.2%).

Earnings vs Market: EUZ's earnings (13% per year) are forecast to grow slower than the German market (22.4% per year).

High Growth Earnings: EUZ's earnings are forecast to grow, but not significantly.

Revenue vs Market: EUZ's revenue (7.2% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: EUZ's revenue (7.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EUZ's Return on Equity is forecast to be low in 3 years time (15.4%).


Next Steps

Past Performance

How has Eckert & Ziegler Strahlen- und Medizintechnik performed over the past 5 years?

18.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EUZ has high quality earnings.

Growing Profit Margin: EUZ's current net profit margins (11.8%) are higher than last year (11.1%).


Past Earnings Growth Analysis

Earnings Trend: EUZ's earnings have grown by 18.5% per year over the past 5 years.

Accelerating Growth: EUZ's earnings growth over the past year (8.2%) is below its 5-year average (18.5% per year).

Earnings vs Industry: EUZ earnings growth over the past year (8.2%) exceeded the Medical Equipment industry 8.2%.


Return on Equity

High ROE: EUZ's Return on Equity (15%) is considered low.


Next Steps

Financial Health

How is Eckert & Ziegler Strahlen- und Medizintechnik's financial position?


Financial Position Analysis

Short Term Liabilities: EUZ's short term assets (€148.5M) exceed its short term liabilities (€39.4M).

Long Term Liabilities: EUZ's short term assets (€148.5M) exceed its long term liabilities (€91.0M).


Debt to Equity History and Analysis

Debt Level: EUZ's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: EUZ's debt to equity ratio has reduced from 18.4% to 0.01% over the past 5 years.

Debt Coverage: EUZ's debt is well covered by operating cash flow (207383.3%).

Interest Coverage: EUZ's interest payments on its debt are well covered by EBIT (40.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Eckert & Ziegler Strahlen- und Medizintechnik current dividend yield, its reliability and sustainability?

1.10%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: EUZ's dividend (1.1%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.26%).

High Dividend: EUZ's dividend (1.1%) is low compared to the top 25% of dividend payers in the German market (3.8%).


Stability and Growth of Payments

Stable Dividend: EUZ's dividends per share have been stable in the past 10 years.

Growing Dividend: EUZ's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (41.2%), EUZ's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: EUZ's dividends in 3 years are forecast to be well covered by earnings (33.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Andreas Eckert (60yo)

no data

Tenure

€976,521

Compensation

Dr. Andreas Eckert, PhD, is the Founder and Managing Partner of ELSA Eckert Life Science Accelerator GmbH. Dr. Exkert is the Founder of Eckert & Ziegler Strahlen & Medizintechnik AG and serves as its Chief ...


CEO Compensation Analysis

Compensation vs Market: Andreas's total compensation ($USD1.10M) is about average for companies of similar size in the German market ($USD1.43M).

Compensation vs Earnings: Andreas's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Andreas Eckert
Chairman of Executive Board & CEOno data€976.52k0.21% 1.6m
Harald Hasselmann
Head of Radiation Therapy Segment & Member of the Executive Board3.5yrs€365.95kno data
Lutz Helmke
Member of Executive Board1.83yrs€452.03kno data
Gunnar Mann
Head of Intragroup Services8.5yrsno datano data
Franklin Yeager
President of Eckert & Ziegler Isotope Products Inc.no datano datano data
Joseph Hathcock
Vice President of Eckert & Ziegler Isotope Products Incno datano datano data
Ivan Simmer
Managing Director of Eckert & Ziegler Cesio s.r.o.6.5yrsno datano data

5.0yrs

Average Tenure

56yo

Average Age

Experienced Management: EUZ's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Frank Perschmann
Member of Supervisory Board1.17yrs€9.00kno data
Wolfgang Maennig
Chairman of Supervisory Board7.17yrs€40.00kno data
Edgar Löffler
Member of Supervisory Board1.5yrs€17.00kno data
Helmut Grothe
Deputy Chairman of the Supervisory Board3yrs€29.00kno data
Albert Rupprecht
Member of Supervisory Board3.17yrs€16.00kno data
Jutta Ludwig
Member of Supervisory Board1.5yrs€17.00kno data

2.3yrs

Average Tenure

67yo

Average Age

Experienced Board: EUZ's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Eckert & Ziegler Strahlen- und Medizintechnik AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Ticker: EUZ
  • Exchange: XTRA
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €798.376m
  • Shares outstanding: 5.15m
  • Website: https://www.ezag.com

Number of Employees


Location

  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Robert-Rössle-Strasse 10
  • Berlin
  • Berlin
  • 13125
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EUZDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 1999
EUZXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURMay 1999
0NZYLSE (London Stock Exchange)YesOrdinary SharesGBEURMay 1999
EUZdBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURMay 1999
EUZETLX (Eurotlx)YesOrdinary SharesITEURMay 1999

Biography

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: Radiation Therapy, Radiopharma, and Isotope Products. The Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment offers small radioactive implants for the treatment of prostate cancer seeds; and tumor radiation devices and eye applicators. This segment’s products and equipment are used by oncologists, radiotherapists, urologists, ophthalmologists, and medical physicists. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine; and supplies various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment provides products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Isotope Products segment offers sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. It also provides custom and one-off design and manufacturing services. In addition, the company offers services for collection, recycling, and disposal of sealed radioactive sources and low activity isotope related waste from hospitals, research institutes, and industries. Eckert & Ziegler Strahlen- und Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 20:53
End of Day Share Price2020/07/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.